RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 23, 2020 /PRNewswire/ -- Findings from a new exploratory sub-analysis of the EMPEROR-Reduced phase III trial showed that Jardiance® (empagliflozin) reduced the risk of adverse cardiovascular and kidney events in adults with heart failure with reduced ejection fraction - with and without
Related News
Strataca Systems®, Ltd. To Present New Data Demonstrating Improved Kidney Function Associated with JuxtaFlow® Renal Negative Pressure Treatment in Animal Models With and Without Congestive Heart Failure
Strataca Systems®, Ltd. To Present New Data Demonstrating Improved Kidney Function Associated with JuxtaFlow® Renal Negative Pressure Treatment in Animal Models With and...
Pharmiweb 2020-10-23Urinalysis Market Worth $2.19 billion by 2027- Exclusive Report Covering Pre and Post COVID-19 Market Analysis by Meticulous Research®
LONDON, Oct. 23, 2020 /PRNewswire/ -- According to a new market research report "Urinalysis Market by Product (Pregnancy & Fertility Test, Dipstick, Reagent, Automatic,...
PR Newswire 2020-10-23Drug Study Offers New Hope to Patients with Both Chronic Kidney Disease and Type 2 Diabetes
Oct. 23, 2020, New York, NY - Patients with diabetic kidney disease can potentially be treated with a new investigational medication that may slow the progress of their...
Public Technologies 2020-10-23Alnylam Presents Positive Results from ILLUMINATE-B Phase 3 Study in Pediatric Patients with Primary Hyperoxaluria Type 1 at the American Society of Nephrology Kidney Week
Oct 22, 2020 Press Release for Alnylam Alnylam Presents Positive Results from ILLUMINATE-B Phase 3 Study in Pediatric Patients with Primary Hyperoxaluria Type 1 at the...
Public Technologies 2020-10-22Can COVID-19 trigger diabetes? Doctors are probing
Mario Buelna, a healthy 28-year-old father, caught a fever and started having trouble breathing in June. He soon tested positive for COVID-19. Weeks later, after what had...
Live Mint 2020-10-22Dicerna Presents Positive New Interim Data From PHYOX™3 Long-Term, Open-Label Extension Study of Nedosiran for Treatment of Primary Hyperoxaluria (PH)
- All Participants Receiving Nedosiran, Regardless of Subtype, Achieved Normalization or Near-Normalization of Urinary Oxalate, a Key PH Measure, by Day 180 in Ongoing,...
Public Technologies 2020-10-22Akebia Presents Results from its PRO2TECT Global Phase 3 Program of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients Not on Dialysis During Late-Breaking Session at American Society of Nephrology Kidney Week 2020 Reimagined
CAMBRIDGE, Mass., Oct. 23, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced the presentation of clinical data from its PRO2TECT global Phase 3...
PR Newswire 2020-10-23Related News
FARXIGA DAPA-CKD Phase III Trial Reduced Worsening of Kidney Function, Risk of Cardiovascular or Renal ...
The Marshall News Messenger
2020-10-23